Commerzbank Aktiengesellschaft FI Has $332,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Commerzbank Aktiengesellschaft FI grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 656 shares of the company’s stock after buying an additional 134 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in IDEXX Laboratories were worth $332,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of IDXX. Atomi Financial Group Inc. lifted its holdings in IDEXX Laboratories by 3.4% during the first quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock worth $344,000 after acquiring an additional 21 shares during the period. Eads & Heald Wealth Management raised its stake in shares of IDEXX Laboratories by 0.8% during the 2nd quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company’s stock worth $1,309,000 after purchasing an additional 22 shares during the period. LRI Investments LLC raised its stake in shares of IDEXX Laboratories by 21.7% during the 2nd quarter. LRI Investments LLC now owns 129 shares of the company’s stock worth $63,000 after purchasing an additional 23 shares during the period. Mather Group LLC. boosted its holdings in shares of IDEXX Laboratories by 3.9% in the 3rd quarter. Mather Group LLC. now owns 617 shares of the company’s stock worth $312,000 after buying an additional 23 shares during the last quarter. Finally, Sovereign Financial Group Inc. grew its position in IDEXX Laboratories by 5.1% during the third quarter. Sovereign Financial Group Inc. now owns 470 shares of the company’s stock valued at $237,000 after buying an additional 23 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $452.27 on Friday. The company has a market capitalization of $37.35 billion, a price-to-earnings ratio of 43.78, a PEG ratio of 4.14 and a beta of 1.33. The business has a 50 day moving average of $486.11 and a 200 day moving average of $490.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a 1-year low of $372.50 and a 1-year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. IDEXX Laboratories’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period last year, the firm earned $2.67 earnings per share. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. JPMorgan Chase & Co. reduced their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Piper Sandler cut their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research note on Wednesday, August 14th. Finally, BTIG Research assumed coverage on IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $574.13.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.